Stock analysts at StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) in a ...

Late-stage pipeline products anticipated to reach the uveitis market during the forecast period will introduce new mechanisms ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

Researchers sought to evaluate differences in ctDNA profiles, use of targeted treatments, and overall survival between Black and White patients with metastatic breast cancer.

Relay Therapeutics, Inc.’s RLAY share price has dipped by 12.66%, which has investors questioning if this is right time to ...

Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine ...

Tyrosine kinase inhibitors (TKIs ... The inhibition of tyrosine kinases blocks the activation of VEGF receptor and platelet-derived growth factor receptor, thereby reducing angiogenesis and ...

Shares of Cogent Biosciences, Inc. (NASDAQ:COGT – Get Free Report) have received an average rating of “Moderate Buy” from the ...

OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...

Revenue in 2024 increased 342%year-over-year to US$134.3 million (RMB980.7 million), attributable in part to Takeda’s option payment and strong ...